Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNC129
MIFTS: 68

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pancreatic Adenocarcinoma

About this section

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 12 29 6 15 17
Adenocarcinoma of the Pancreas 12
Pancreas Adenocarcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4074
NCIt 49 C8294
SNOMED-CT 67 700423003
UMLS 71 C0281361
Sources

Summaries for Pancreatic Adenocarcinoma

About this section
Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreatic Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic cancer and pancreatic ductal adenocarcinoma, and has symptoms including pruritus, abdominal pain and icterus. An important gene associated with Pancreatic Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Desflurane and Anesthetics, General have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Pancreatic Adenocarcinoma

About this section

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 689)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 35.6 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
2 pancreatic ductal adenocarcinoma 35.0 VEGFA TP53 STAT3 SRC SMAD4 MUC4
3 adenocarcinoma 34.7 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
4 pancreatitis 32.8 TP53 SMAD4 MUC4 KRAS HRAS CDKN2A
5 breast cancer 32.8 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
6 colorectal cancer 32.8 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
7 hepatocellular carcinoma 32.5 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
8 cholangiocarcinoma 32.5 TP53 STAT3 SMAD4 PIK3CA MUC4 KRAS
9 esophageal cancer 32.4 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
10 endometrial cancer 32.4 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
11 ovarian cancer 32.3 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
12 prostate cancer 32.3 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
13 melanoma 32.3 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
14 neuroblastoma 32.3 VEGFA TP53 STAT3 SRC PIK3CA HRAS
15 bile duct cancer 32.3 VEGFA TP53 SMAD4 MUC4 KRAS HRAS
16 gastric cancer 32.2 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
17 ovarian serous cystadenocarcinoma 32.2 VEGFA TP53 SMAD4 PIK3CA KRAS HRAS
18 gastric adenocarcinoma 32.2 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
19 intrahepatic cholangiocarcinoma 32.2 TP53 SMAD4 MUC4 KRAS ERBB2 EGFR
20 exanthem 32.2 VEGFA KRAS HRAS ERBB2 EGFR AKT1
21 squamous cell carcinoma 32.2 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
22 cervical cancer 32.2 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
23 glioblastoma multiforme 32.1 VEGFA TP53 STAT3 SRC PIK3CA KRAS
24 adenoma 32.1 TP53 TGFBR2 SMAD4 PIK3CA KRAS GNAS
25 lung cancer susceptibility 3 32.1 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
26 lynch syndrome 32.1 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
27 in situ carcinoma 32.1 TP53 PIK3CA HRAS ERBB2 EGFR EGF
28 pancreatic ductal carcinoma 32.1 VEGFA TP53 SMAD4 ERBB2 EGFR EGF
29 suppression of tumorigenicity 12 32.1 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
30 leukemia, acute myeloid 32.0 VEGFA TP53 STAT3 SRC PIK3CA KRAS
31 pancreas disease 32.0 TP53 KRAS HRAS AKT1
32 lymphoma 32.0 TP53 STAT3 PIK3CA EGFR CDKN2A BRCA2
33 cystadenocarcinoma 32.0 VEGFA TP53 PIK3CA HRAS ERBB2 AKT1
34 peutz-jeghers syndrome 32.0 TP53 TGFBR2 SMAD4 GNAS EGFR CTNNB1
35 mucinous adenocarcinoma 32.0 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
36 colon adenocarcinoma 32.0 VEGFA TP53 SMAD4 PIK3CA KRAS ERBB2
37 ovary adenocarcinoma 31.9 VEGFA TP53 SMAD4 PIK3CA KRAS HRAS
38 gallbladder cancer 31.9 VEGFA TP53 TGFBR2 STAT3 SMAD4 PIK3CA
39 gastrointestinal stromal tumor 31.9 VEGFA TP53 STAT3 KRAS ERBB2 EGFR
40 leukemia, chronic lymphocytic 31.9 VEGFA TP53 STAT3 SRC PIK3CA KRAS
41 serous cystadenocarcinoma 31.8 VEGFA TP53 PIK3CA KRAS HRAS ERBB2
42 myeloma, multiple 31.8 VEGFA TP53 STAT3 SRC KRAS HRAS
43 hereditary breast ovarian cancer syndrome 31.7 TP53 SMAD4 KRAS HRAS ERBB2 CDKN2A
44 hepatitis b 31.7 TP53 STAT3 SRC PIK3CA KRAS AKT1
45 gallbladder disease 31.7 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
46 renal cell carcinoma, nonpapillary 31.7 VEGFA TP53 STAT3 PIK3CA HRAS EGFR
47 colorectal adenocarcinoma 31.7 VEGFA TP53 STAT3 KRAS HRAS ERBB2
48 bladder urothelial carcinoma 31.7 VEGFA TP53 PIK3CA KRAS HRAS ERBB2
49 papilloma 31.7 VEGFA TP53 KRAS EGFR CDKN2A
50 body mass index quantitative trait locus 11 31.7 VEGFA TP53 STAT3 SRC GNAS CTNNB1

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma
Sources

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

About this section

UMLS symptoms related to Pancreatic Adenocarcinoma:


pruritus, abdominal pain, icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.88 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.88 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.88 KRAS
4 Decreased viability GR00106-A-0 10.88 KRAS
5 Decreased viability GR00107-A-1 10.88 TGFBR2
6 Decreased viability GR00221-A-1 10.88 EGFR HRAS KRAS PIK3CA AKT1 CDKN2A
7 Decreased viability GR00221-A-2 10.88 HRAS KRAS PIK3CA AKT1
8 Decreased viability GR00221-A-3 10.88 HRAS AKT1 CDKN2A ERBB2 TGFBR2
9 Decreased viability GR00221-A-4 10.88 EGFR PIK3CA AKT1 CDKN2A ERBB2 TGFBR2
10 Decreased viability GR00249-S 10.88 AKT1 TGFBR2
11 Decreased viability GR00301-A 10.88 KRAS
12 Decreased viability GR00381-A-1 10.88 KRAS
13 Decreased viability GR00402-S-2 10.88 PIK3CA TGFBR2
14 Decreased cell migration GR00055-A-1 9.86 AKT1 MAP2K2
15 Decreased cell migration GR00055-A-3 9.86 EGFR HRAS PIK3CA
16 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 GNAS MAP2K2 SMAD4 TGFBR2
17 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.55 AKT1 BRCA2 CDKN2A CTNNB1 EGF EGFR
2 growth/size/body region MP:0005378 10.54 AKT1 BRCA2 CDKN2A CTNNB1 EGF EGFR
3 behavior/neurological MP:0005386 10.53 AKT1 BRCA2 CDKN2A CTNNB1 ERBB2 GNAS
4 cellular MP:0005384 10.52 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
5 cardiovascular system MP:0005385 10.5 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GNAS
6 integument MP:0010771 10.5 AKT1 BRCA2 CDKN2A CTNNB1 EGF EGFR
7 homeostasis/metabolism MP:0005376 10.47 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
8 digestive/alimentary MP:0005381 10.45 BRCA2 CDKN2A CTNNB1 EGF EGFR ERBB2
9 embryo MP:0005380 10.44 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
10 mortality/aging MP:0010768 10.44 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
11 immune system MP:0005387 10.43 AKT1 BRCA2 CDKN2A CTNNB1 EGF EGFR
12 craniofacial MP:0005382 10.42 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
13 neoplasm MP:0002006 10.41 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
14 hematopoietic system MP:0005397 10.39 AKT1 BRCA2 CDKN2A CTNNB1 EGFR GNAS
15 nervous system MP:0003631 10.36 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
16 muscle MP:0005369 10.31 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GNAS
17 normal MP:0002873 10.28 AKT1 BRCA2 CTNNB1 EGF EGFR ERBB2
18 liver/biliary system MP:0005370 10.26 AKT1 CDKN2A CTNNB1 EGFR GNAS KRAS
19 limbs/digits/tail MP:0005371 10.24 BRCA2 CTNNB1 EGFR ERBB2 GNAS KRAS
20 adipose tissue MP:0005375 10.23 AKT1 EGFR GNAS MAP2K2 PIK3CA STAT3
21 reproductive system MP:0005389 10.1 AKT1 BRCA2 CDKN2A CTNNB1 EGF EGFR
22 no phenotypic analysis MP:0003012 10.09 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
23 renal/urinary system MP:0005367 10.02 CTNNB1 EGFR GNAS HRAS KRAS SMAD4
24 respiratory system MP:0005388 9.97 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GNAS
25 pigmentation MP:0001186 9.91 CDKN2A CTNNB1 EGFR KRAS SRC TGFBR2
26 skeleton MP:0005390 9.89 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
27 vision/eye MP:0005391 9.4 CDKN2A CTNNB1 EGF EGFR KRAS MAP2K2
Sources

Drugs & Therapeutics for Pancreatic Adenocarcinoma

About this section

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desflurane Approved Phase 4 57041-67-5 42113
2 Anesthetics, General Phase 4
3 Anesthetics, Inhalation Phase 4
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
6
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
7
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
8
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
9
Enoxaparin Approved Phase 2, Phase 3 9005-49-6 772
10
Ethanol Approved Phase 3 64-17-5 702
11
tannic acid Approved Phase 3 1401-55-4
12
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
13
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
14
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
15
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
16
Dalteparin Approved Phase 3 9005-49-6
17
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
18
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
19
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Rubitecan Investigational Phase 3 91421-42-0
22
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
23
tipifarnib Investigational Phase 3 192185-72-1 159324
24
Irofulven Investigational Phase 3 158440-71-2
25 Cyclooxygenase 2 Inhibitors Phase 3
26 Cyclooxygenase Inhibitors Phase 3
27 ON 01910 Phase 3
28 Tubulin Modulators Phase 3
29 Antimitotic Agents Phase 3
30
asparaginase Phase 3
31 Anti-Infective Agents, Local Phase 3
32 Calcium, Dietary Phase 3
33 glucocorticoids Phase 3
34 Folate Phase 3
35 Vitamin B9 Phase 3
36 Platelet Aggregation Inhibitors Phase 3
37 Fibrinolytic Agents Phase 3
38 Heparin, Low-Molecular-Weight Phase 3
39 Anticoagulants Phase 3
40 calcium heparin Phase 3
41 Neurotransmitter Agents Phase 3
42 Purinergic P2Y Receptor Antagonists Phase 3
43
Calcium Nutraceutical Phase 3 7440-70-2 271
44
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
45
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
46
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Dipyridamole Approved Phase 2 58-32-2 3108
49
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
50
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 838)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
3 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
4 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
5 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
6 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
7 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
8 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
9 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
12 Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
13 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
14 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
15 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVACâ„¢-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
16 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
17 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
18 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
19 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Unknown status NCT02514928 Phase 3
20 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
21 A Prospective, Multi-centric, Phase â…¢, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Unknown status NCT02506842 Phase 3 nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
22 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
23 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
24 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
25 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
26 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
27 European Study Group For Pancreatic Cancer - Trial 3 Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
28 A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
29 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
30 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
31 Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen Completed NCT02923921 Phase 3 FOLFOX
32 A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
33 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
34 Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
35 A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
36 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
37 Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
38 Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. Completed NCT00003029 Phase 3 cisplatin;fluorouracil
39 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
40 A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
41 A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
42 An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
43 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
44 Randomized Controlled Study: Comparison Between Extended and Standard Pancreatoduodenectomy Completed NCT00679913 Phase 3
45 A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC] Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
46 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
47 A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
48 Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
49 A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
50 Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Sources

Genetic Tests for Pancreatic Adenocarcinoma

About this section

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29
Sources

Anatomical Context for Pancreatic Adenocarcinoma

About this section

MalaCards organs/tissues related to Pancreatic Adenocarcinoma:

40
Pancreas, Liver, Lymph Node, Lung, T Cells, Endothelial, Testes
Sources

Publications for Pancreatic Adenocarcinoma

About this section

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 7125)
# Title Authors PMID Year
1
Perioperative Nursing of Patients with Pancreatic Cancer Treated with a Nanoknife. 61
32385017 2020
2
Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. 61
32389710 2020
3
Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study. 61
32534978 2020
4
Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. 61
32485509 2020
5
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells. 61
32415418 2020
6
Pancreatic Intraepithelial Neoplasia (PanIN) as a Morphologic Marker of Pancreatobiliary Type of Ampullary Carcinoma. 61
31642034 2020
7
Transsplenic Microwave Ablation of Pancreatic Adenocarcinoma in a Morbidly Obese Patient. 61
32564895 2020
8
Prognostic prediction of a 12-methylation gene-based risk score system on pancreatic adenocarcinoma. 61
32565937 2020
9
Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative course. 61
32569179 2020
10
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. 61
31607641 2020
11
The utility of immunohistochemical testing for mismatch repair proteins in fine needle aspiration specimens of pancreatic adenocarcinoma. 61
32570025 2020
12
Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. 61
32382348 2020
13
The Impact of the Depth of Venous Invasion on Survival Following Pancreatoduodenectomy for Pancreatic Cancer: a Meta-analysis of Available Evidence. 61
31062188 2020
14
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. 61
31338636 2020
15
Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and its Pro-nitroxide Conjugate through ROS-mediated Mitochondrial Dysfunction and G2/M Cell-cycle Arrest in Human Pancreatic Cancer. 61
32449075 2020
16
The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation. 61
32507974 2020
17
Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions. 61
32531402 2020
18
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). 61
32535711 2020
19
GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets. 61
32060895 2020
20
Development of an autophagy-related signature in pancreatic adenocarcinoma. 61
32203889 2020
21
The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. 61
32493354 2020
22
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. 61
32509815 2020
23
Endoscopic Management of Malignant Biliary Stricture. 61
32532018 2020
24
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. 61
32575903 2020
25
Increasing Yttrium-90 Dose Conformality Using Proximal Radioembolization Enabled by Distal Angiosomal Truncation for the Treatment of Hepatic Malignancy. 61
32381352 2020
26
Painful Panniculitis and Polyarthritis in Pancreatic Adenocarcinoma: A Case Report. 61
32496359 2020
27
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. 61
31407252 2020
28
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. 61
32362489 2020
29
Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? 61
32018143 2020
30
Biliary palliation for unresectable pancreatic adenocarcinoma. 61
32561178 2020
31
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. 61
32557396 2020
32
Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. 61
32222341 2020
33
Immunotherapy for pancreatic cancer: A 2020 update. 61
32247999 2020
34
The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. 61
32533054 2020
35
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. 61
32541630 2020
36
Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. 61
32423820 2020
37
The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. 61
32490170 2020
38
Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma. 61
31236851 2020
39
Meta-analysis of MRI for the diagnosis of liver metastasis in patients with pancreatic adenocarcinoma. 61
31664776 2020
40
CSN6 inhibition suppresses pancreatic adenocarcinoma metastasis via destabilizing the c-Fos protein. 61
32289284 2020
41
Response to letter "resectable pancreas adenocarcinoma: the longer the wait time, the longer the oncologic survival?" 61
32291176 2020
42
Impact of surgical wait times on oncologic outcomes in resectable pancreas adenocarcinoma. 61
31732464 2020
43
Tumor targeting vitamin B12 derivatives for X-ray induced treatment of pancreatic adenocarcinoma. 61
31899377 2020
44
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. 61
32350413 2020
45
Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. 61
31894482 2020
46
Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. 61
31898105 2020
47
Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. 61
32129882 2020
48
ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy. 61
32172332 2020
49
Successful Management of Hemosuccus Pancreaticus due to Pancreatic Adenocarcinoma by Chemoradiotherapy. 61
32493849 2020
50
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. 61
31895709 2020
Sources

Variations for Pancreatic Adenocarcinoma

About this section

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

6 (show top 50) (show all 415) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
3 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
4 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
5 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
6 TP53 NM_001126112.2(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
7 TP53 NM_001126112.2(TP53):c.713G>C (p.Cys238Ser)SNV Pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
8 TP53 NM_001126112.2(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
9 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
10 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
11 TP53 NM_001126112.2(TP53):c.644G>T (p.Ser215Ile)SNV Pathogenic 376660 rs587782177 17:7578205-7578205 17:7674887-7674887
12 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
13 TP53 NM_001126112.2(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
14 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
15 SMAD4 NM_005359.6(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
16 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
17 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
18 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
19 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
20 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
21 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
22 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
23 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
24 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
25 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
26 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
27 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
28 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
29 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
30 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
31 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
32 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
33 TP53 NM_001126112.2(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
34 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
35 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
36 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
37 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
38 TP53 NM_001126112.2(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
39 TP53 NM_001126112.2(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
40 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
41 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
42 TP53 NM_001126112.2(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
43 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
44 TP53 NM_001126112.2(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
45 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
46 TP53 NM_001126112.2(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
47 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
48 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile)SNV Pathogenic/Likely pathogenic 375994 rs1057519738 17:37881332-37881332 17:39725079-39725079
49 TP53 NM_001126112.2(TP53):c.527G>A (p.Cys176Tyr)SNV Pathogenic/Likely pathogenic 186451 rs786202962 17:7578403-7578403 17:7675085-7675085
50 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp)SNV Pathogenic/Likely pathogenic 156446 rs587777790 3:178917478-178917478 3:179199690-179199690
Sources

Expression for Pancreatic Adenocarcinoma

About this section
Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.
Sources

Pathways for Pancreatic Adenocarcinoma

About this section

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.4 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
2
Innate Immune System 65
Show member pathways
 14.26 VEGFA TP53 STAT3 SRC PIK3CA MUC4
3
ERK Signaling 63
Show member pathways
 14.06 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
4
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 14.02 TP53 SRC MAP2K2 KRAS HRAS GNAS
5
HIV Life Cycle 65
Show member pathways
 13.97 TGFBR2 STAT3 SRC SMAD4 PIK3CA MUC4
6
PEDF Induced Signaling 63
Show member pathways
 13.92 TP53 TGFBR2 STAT3 SRC SMAD4 MAP2K2
7
GPCR Pathway 63
Show member pathways
 13.92 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
8
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.81 TGFBR2 SRC SMAD4 MAP2K2 KRAS HRAS
9
TGF-Beta Pathway 63
Show member pathways
 13.79 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
10
Developmental Biology 65
Show member pathways
 13.77 VEGFA STAT3 SRC SMAD4 PIK3CA MAP2K2
11
Integrin Pathway 63
Show member pathways
 13.68 VEGFA TGFBR2 STAT3 SRC PIK3CA MAP2K2
12
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.66 TP53 SRC PIK3CA KRAS HRAS ERBB2
13
Akt Signaling 63
Show member pathways
 13.66 TP53 STAT3 SRC KRAS HRAS GNAS
14
Cytokine Signaling in Immune system 65
Show member pathways
 13.64 VEGFA TP53 STAT3 SRC PIK3CA MAP2K2
15
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.57 VEGFA TP53 SRC PIK3CA KRAS HRAS
16
CREB Pathway 63
Show member pathways
 13.56 SRC MAP2K2 KRAS HRAS GNAS ERBB2
17
PAK Pathway 63
Show member pathways
 13.56 TGFBR2 SRC SMAD4 KRAS HRAS ERBB2
18
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.55 VEGFA SRC MAP2K2 KRAS HRAS GNAS
19
IL-2 Pathway 63
Show member pathways
 13.49 TP53 STAT3 SRC MAP2K2 KRAS HRAS
20
Parkinson disease 36
Show member pathways
 13.39 TP53 PIK3CA MAP2K2 KRAS HRAS GNAS
21
TNFR1 Pathway 63
Show member pathways
 13.35 VEGFA TP53 SRC PIK3CA MAP2K2 KRAS
22
Phospholipase-C Pathway 63
Show member pathways
 13.34 TP53 SRC MAP2K2 KRAS HRAS GNAS
23
G-Beta Gamma Signaling 63
Show member pathways
 13.33 VEGFA SRC MAP2K2 KRAS HRAS GNAS
24
GAB1 signalosome 65
Show member pathways
 13.31 TP53 SRC PIK3CA ERBB2 EGFR EGF
25
p70S6K Signaling 63
Show member pathways
 13.3 STAT3 MAP2K2 KRAS HRAS GNAS EGFR
26
DAG and IP3 signaling 65
Show member pathways
 13.29 SRC SMAD4 KRAS HRAS GNAS EGFR
27
fMLP Pathway 63
Show member pathways
 13.29 VEGFA TP53 STAT3 SRC MAP2K2 KRAS
28
PI3K-Akt signaling pathway 36
Show member pathways
 13.27 VEGFA TP53 PIK3CA MAP2K2 KRAS HRAS
29
TCR Signaling (Qiagen) 63
Show member pathways
 13.19 TP53 STAT3 SRC MAP2K2 KRAS HRAS
30
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.17 VEGFA TGFBR2 STAT3 SRC PIK3CA MAP2K2
31
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.16 TGFBR2 SRC MAP2K2 KRAS HRAS CTNNB1
32
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.16 TGFBR2 STAT3 SRC PIK3CA MAP2K2 KRAS
33
Focal Adhesion 36 1
Show member pathways
 13.16 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
34
Aldosterone synthesis and secretion 36
Show member pathways
 13.14 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
35
CCR5 Pathway in Macrophages 63
Show member pathways
 13.12 STAT3 SRC PIK3CA KRAS HRAS GNAS
36
Development Angiotensin activation of ERK 22
Show member pathways
 13.11 SRC PIK3CA MAP2K2 KRAS HRAS EGFR
37
MAPK Erk Pathway 66
Show member pathways
 13.08 STAT3 SRC PIK3CA MAP2K2 KRAS HRAS
38
MAPK signaling pathway 36 1
13.07 VEGFA TP53 TGFBR2 MAP2K2 KRAS HRAS
39
Beta-Adrenergic Signaling 63
Show member pathways
 13.06 SRC MAP2K2 KRAS HRAS GNAS CTNNB1
40
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.05 TP53 TGFBR2 STAT3 SRC SMAD4 PIK3CA
41
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 13.04 TP53 SRC PIK3CA KRAS HRAS ERBB2
42
Development HGF signaling pathway 22
Show member pathways
 13.02 TP53 STAT3 SRC PIK3CA MAP2K2 KRAS
43
Ras signaling pathway 36
Show member pathways
 13.02 VEGFA SRC PIK3CA MAP2K2 KRAS HRAS
44
Human cytomegalovirus infection 36
Show member pathways
 13.01 VEGFA TP53 STAT3 SRC PIK3CA MAP2K2
45
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.99 STAT3 PIK3CA MAP2K2 KRAS HRAS AKT1
46
Apoptosis Modulation and Signaling 1
Show member pathways
 12.98 TP53 PIK3CA MAP2K2 KRAS HRAS CDKN2A
47
G-AlphaQ Signaling 63
Show member pathways
 12.98 STAT3 SRC MAP2K2 KRAS HRAS GNAS
48
4-1BB Pathway 63
Show member pathways
 12.96 TP53 STAT3 MAP2K2 KRAS HRAS EGFR
49
nNOS Signaling in Skeletal Muscle 63
Show member pathways
 12.95 STAT3 SRC SMAD4 KRAS HRAS EGFR
50
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.95 SRC PIK3CA MAP2K2 KRAS HRAS GNAS
Sources

GO Terms for Pancreatic Adenocarcinoma

About this section

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.27 VEGFA TP53 TGFBR2 SRC PIK3CA MUC4
2 plasma membrane GO:0005886 10.1 TGFBR2 STAT3 SRC PIK3CA MUC4 KRAS
3 cytosol GO:0005829 9.83 TP53 TGFBR2 STAT3 SRC SMAD4 PIK3CA
4 transcription factor complex GO:0005667 9.73 TP53 STAT3 SMAD4 CTNNB1
5 focal adhesion GO:0005925 9.72 SRC MAP2K2 KRAS EGFR CTNNB1
6 receptor complex GO:0043235 9.71 TGFBR2 ERBB2 EGFR EGF
7 perinuclear region of cytoplasm GO:0048471 9.7 SRC MAP2K2 HRAS GNAS ERBB2 EGFR
8 cytoplasm GO:0005737 9.55 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 VEGFA STAT3 SRC KRAS HRAS GNAS
2 cell differentiation GO:0030154 10.26 VEGFA TGFBR2 SRC SMAD4 EGFR CTNNB1
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 VEGFA TP53 STAT3 SMAD4 HRAS EGFR
4 regulation of transcription by RNA polymerase II GO:0006357 10.24 VEGFA TP53 STAT3 SMAD4 ERBB2 EGFR
5 apoptotic process GO:0006915 10.2 TP53 TGFBR2 HRAS CEACAM6 CDKN2A AKT1
6 negative regulation of apoptotic process GO:0043066 10.17 VEGFA TP53 SRC EGFR CTNNB1 AKT1
7 protein phosphorylation GO:0006468 10.17 TGFBR2 SRC PIK3CA MAP2K2 ERBB2 EGFR
8 intracellular signal transduction GO:0035556 10.14 SRC SMAD4 ERBB2 EGFR AKT1
9 positive regulation of apoptotic process GO:0043065 10.12 TP53 SRC CTNNB1 CDKN2A AKT1
10 phosphorylation GO:0016310 10.09 TGFBR2 STAT3 SRC PIK3CA MAP2K2 ERBB2
11 response to drug GO:0042493 10.08 TP53 TGFBR2 STAT3 SRC GNAS CTNNB1
12 negative regulation of cell proliferation GO:0008285 10.08 TP53 TGFBR2 STAT3 SMAD4 HRAS CTNNB1
13 negative regulation of gene expression GO:0010629 10.07 VEGFA TP53 MAP2K2 HRAS CTNNB1 AKT1
14 cytokine-mediated signaling pathway GO:0019221 10.05 VEGFA TP53 STAT3 PIK3CA KRAS AKT1
15 in utero embryonic development GO:0001701 10.04 VEGFA TP53 TGFBR2 SMAD4 CTNNB1
16 protein autophosphorylation GO:0046777 10.03 SRC ERBB2 EGFR AKT1
17 positive regulation of protein kinase B signaling GO:0051897 10.02 SRC PIK3CA ERBB2 EGFR EGF
18 MAPK cascade GO:0000165 10.02 MAP2K2 KRAS HRAS ERBB2 EGFR EGF
19 cellular response to hypoxia GO:0071456 10 VEGFA TP53 SRC AKT1
20 positive regulation of cell migration GO:0030335 10 VEGFA STAT3 HRAS EGFR EGF CEACAM6
21 positive regulation of transcription, DNA-templated GO:0045893 10 TP53 STAT3 SRC SMAD4 MAP2K2 EGFR
22 positive regulation of MAPK cascade GO:0043410 9.99 HRAS ERBB2 EGF CTNNB1
23 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.97 SRC MUC4 KRAS HRAS
24 transforming growth factor beta receptor signaling pathway GO:0007179 9.97 TP53 TGFBR2 SRC SMAD4
25 positive regulation of protein phosphorylation GO:0001934 9.97 VEGFA KRAS HRAS ERBB2 EGFR AKT1
26 lung development GO:0030324 9.96 VEGFA TGFBR2 EGFR CTNNB1
27 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 VEGFA TP53 SRC EGF
28 peptidyl-tyrosine phosphorylation GO:0018108 9.96 SRC MAP2K2 ERBB2 EGFR EGF
29 activation of protein kinase activity GO:0032147 9.95 VEGFA TGFBR2 PIK3CA MAP2K2
30 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.94 VEGFA PIK3CA EGFR AKT1
31 liver development GO:0001889 9.94 PIK3CA KRAS HRAS EGFR
32 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.93 VEGFA SRC AKT1
33 Ras protein signal transduction GO:0007265 9.93 TP53 KRAS HRAS CDKN2A
34 cell proliferation GO:0008283 9.93 STAT3 SRC SMAD4 CTNNB1 BRCA2 AKT1
35 vasculogenesis GO:0001570 9.92 VEGFA TGFBR2 CTNNB1
36 negative regulation of neuron death GO:1901215 9.92 STAT3 CTNNB1 AKT1
37 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.91 VEGFA SRC PIK3CA
38 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 TGFBR2 EGFR AKT1
39 positive regulation of cell adhesion GO:0045785 9.91 VEGFA SRC ERBB2
40 positive regulation of epithelial cell proliferation GO:0050679 9.91 VEGFA HRAS ERBB2 EGFR
41 regulation of cell proliferation GO:0042127 9.91 TP53 TGFBR2 STAT3 SRC SMAD4 EGFR
42 T cell costimulation GO:0031295 9.9 SRC PIK3CA AKT1
43 positive regulation of cell proliferation GO:0008284 9.9 VEGFA TGFBR2 STAT3 KRAS HRAS ERBB2
44 positive regulation of epithelial to mesenchymal transition GO:0010718 9.89 TGFBR2 SMAD4 CTNNB1
45 cellular response to epidermal growth factor stimulus GO:0071364 9.89 ERBB2 EGFR AKT1
46 negative regulation of Notch signaling pathway GO:0045746 9.89 EGFR EGF AKT1
47 cellular response to reactive oxygen species GO:0034614 9.88 SRC EGFR AKT1
48 phosphatidylinositol 3-kinase signaling GO:0014065 9.88 PIK3CA ERBB2 AKT1
49 cellular response to growth factor stimulus GO:0071363 9.88 TGFBR2 ERBB2 EGFR CTNNB1 AKT1
50 gastrulation GO:0007369 9.87 TP53 TGFBR2 SMAD4

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 VEGFA TP53 TGFBR2 STAT3 SRC SMAD4
2 ATP binding GO:0005524 10.1 TP53 TGFBR2 SRC PIK3CA MAP2K2 ERBB2
3 identical protein binding GO:0042802 9.97 VEGFA TP53 STAT3 SMAD4 ERBB2 EGFR
4 nucleotide binding GO:0000166 9.96 TGFBR2 SRC PIK3CA MAP2K2 KRAS HRAS
5 protein kinase activity GO:0004672 9.93 TGFBR2 SRC MAP2K2 ERBB2 EGFR AKT1
6 enzyme binding GO:0019899 9.91 TP53 SRC EGFR CTNNB1 AKT1
7 protein C-terminus binding GO:0008022 9.77 SRC HRAS ERBB2 CTNNB1 BRCA2
8 protein tyrosine kinase activity GO:0004713 9.73 SRC MAP2K2 ERBB2 EGFR
9 RNA polymerase II transcription factor binding GO:0001085 9.7 TP53 SMAD4 CTNNB1
10 protein kinase binding GO:0019901 9.7 TP53 STAT3 SRC EGFR CTNNB1 CDKN2A
11 disordered domain specific binding GO:0097718 9.65 TP53 CTNNB1 CDKN2A
12 kinase activity GO:0016301 9.56 TGFBR2 SRC PIK3CA MAP2K2 ERBB2 EGFR
13 nitric-oxide synthase regulator activity GO:0030235 9.54 EGFR AKT1
14 protein phosphatase binding GO:0019903 9.02 TP53 STAT3 ERBB2 EGFR CTNNB1
Sources

Sources for Pancreatic Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....